One of my "Explore Portfolio" speculation stocks, NanoViricides (Ticker and my charts at NNVC), is soaring on a recent batch of great news.
You can read a summary of the news here. Excerpts:
- NanoViricides Signs a Non-Disclosure Agreement with the Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCide® and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus
- The Company has already shown that the injectable and oral FluCide drug candidates are substantially more effective than oseltamivir (Tamiflu®) in controlling influenza A virus infections in a highly lethal animal model using two unrelated subtypes of influenza A, namely H1N1 and H3N2.
- NanoViricides Receives Notification that Clinical Coordinators Have Been Appointed by The European Medicine Agency to Review the Company's Upcoming DengueCide Orphan Drug Designation Application
- There is currently neither an effective drug treatment nor a vaccine for dengue virus infection.
Disclosure: I am long NNVC.